Literature DB >> 17405761

Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis.

T Sokka1, H Mäkinen, P Hannonen, T Pincus.   

Abstract

OBJECTIVE: To analyse the proportion of individuals in the general population over age 50 who do not meet American College of Rheumatology (ACR) criteria for rheumatoid arthritis (RA) remission, and OMERACT criteria for minimal disease activity (MDA), and to compare results to RA patients.
METHODS: A self-report questionnaire was completed by 1400 community control subjects and 1705 RA patients, including the Health Assessment Questionnaire (HAQ), gradual rating scales for pain, fatigue and global health, duration of morning stiffness and painful joints. The prevalence of 4/6 ACR remission criteria and 4/7 OMERACT criteria for MDA was analysed in community control subjects and patients with RA over age 50.
RESULTS: For ACR criteria, 76% of control subjects reported painful joints, 37% morning stiffness, 62% pain and 66% fatigue, vs 94, 65, 84 and 84% of patients with RA. MDA criteria were not met by 64% of control subjects for painful joints, 38% for pain, 45% for global health and 18% for HAQ, vs 89, 60, 69 and 52% of RA patients. The four ACR remission criteria were met by only 15% of control subjects over age 50 and 3% of RA patients, and MDA criteria by 28% of controls and 7% of patients.
CONCLUSIONS: The majority of community population over age 50 did not meet criteria for remission or MDA in RA. Although a self-report format may differ from results involving an assessor, the current criteria may not be accurate to identify remission or MDA in people with RA who are older than age 50.

Entities:  

Mesh:

Year:  2007        PMID: 17405761     DOI: 10.1093/rheumatology/kem051

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  16 in total

1.  Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study.

Authors:  Fabio Massimo Perrotta; Antonia De Socio; Silvia Scriffignano; Ennio Lubrano
Journal:  Clin Rheumatol       Date:  2018-02-21       Impact factor: 2.980

Review 2.  Challenges in the management of older patients with inflammatory rheumatic diseases.

Authors:  Marloes van Onna; Annelies Boonen
Journal:  Nat Rev Rheumatol       Date:  2022-03-21       Impact factor: 20.543

Review 3.  Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference.

Authors:  Lilian H D van Tuyl; Steven C Vlad; David T Felson; George Wells; Maarten Boers
Journal:  Arthritis Rheum       Date:  2009-05-15

Review 4.  Rheumatoid arthritis in the elderly in the era of tight control.

Authors:  Martin Soubrier; Zuzana Tatar; Marion Couderc; Sylvain Mathieu; Jean-Jacques Dubost
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

5.  Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.

Authors:  William J Martin; Man Shim; Harold E Paulus; Sandeep Chaudhari; JingYuan Feng; David Elashoff; Theodore J Hahn; Veena K Ranganath
Journal:  J Clin Rheumatol       Date:  2014-09       Impact factor: 3.517

6.  Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.

Authors:  Veena K Ranganath; Paul Maranian; David A Elashoff; Thasia Woodworth; Dinesh Khanna; Theodore Hahn; Catherine Sarkisian; Joel M Kremer; Daniel E Furst; Harold E Paulus
Journal:  Rheumatology (Oxford)       Date:  2013-06-27       Impact factor: 7.580

7.  Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective.

Authors:  Márta Péntek; Bernadette Rojkovich; László Czirják; Pál Géher; Péter Keszthelyi; Attila Kovács; László Kovács; Zita Szabó; Zoltán Szekanecz; László Tamási; Ágnes Edit Tóth; Ilona Ujfalussy; Noémi Vártokné Hevér; Bálint Strbák; Petra Baji; Valentin Brodszky; László Gulácsi
Journal:  Eur J Health Econ       Date:  2014-05-16

8.  Remission makes its way to rheumatology.

Authors:  Tuulikki Sokka; Heidi Mäkinen
Journal:  Arthritis Res Ther       Date:  2010-07-14       Impact factor: 5.156

9.  Sustained rheumatoid arthritis remission is uncommon in clinical practice.

Authors:  Femke H M Prince; Vivian P Bykerk; Nancy A Shadick; Bing Lu; Jing Cui; Michelle Frits; Christine K Iannaccone; Michael E Weinblatt; Daniel H Solomon
Journal:  Arthritis Res Ther       Date:  2012-03-19       Impact factor: 5.156

10.  Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH.

Authors:  Jessica A B van Nies; Celina Alves; Audrey L S Radix-Bloemen; Cécile Gaujoux-Viala; Tom W J Huizinga; Johanna M W Hazes; Elisabeth Brouwer; Bruno Fautrel; Annette H M van der Helm-van Mil
Journal:  Arthritis Res Ther       Date:  2015-04-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.